{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:42:49Z","timestamp":1765233769028,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11845-024-03704-7","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:02:04Z","timestamp":1715774524000},"page":"2589-2595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension \u2014 an observer blinded active-control trial"],"prefix":"10.1007","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-6423","authenticated-orcid":false,"given":"David","family":"Brinkman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"McSwiney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"issue":"11","key":"3704_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY et al (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121(11):2081\u20132090","journal-title":"Ophthalmology"},{"key":"3704_CR2","first-page":"40","volume":"110","author":"C Baudouin","year":"2012","unstructured":"Baudouin C, Denoyer A, Desbenoit N et al (2012) In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 110:40\u201363","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"11","key":"3704_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050180","volume":"7","author":"F Brignole-Baudouin","year":"2012","unstructured":"Brignole-Baudouin F, Desbenoit N, Hamm G et al (2012) A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. PLoS ONE 7(11)","journal-title":"PLoS ONE"},{"issue":"4","key":"3704_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12325-013-0021-8","volume":"30","author":"S Lee","year":"2013","unstructured":"Lee S, Kim MK, Choi HJ et al (2013) Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface. Adv Ther 30(4):420\u2013429","journal-title":"Adv Ther"},{"issue":"5","key":"3704_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN (2008) Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 17(5):350\u2013355","journal-title":"J Glaucoma"},{"issue":"2","key":"3704_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ophtha.2008.09.004","volume":"116","author":"CO Okeke","year":"2009","unstructured":"Okeke CO, Quigley HA, Jampel HD et al (2009) Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology 116(2):191\u2013199","journal-title":"Ophthalmology"},{"issue":"11","key":"3704_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/bjophthalmol-2017-311544","volume":"102","author":"DW Steven","year":"2018","unstructured":"Steven DW, Alaghband P, Lim KS (2018) Preservatives in glaucoma medication. Br J Ophthalmol 102(11):1497\u20131503","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"3704_CR8","first-page":"1512","volume":"104","author":"A Hedengran","year":"2020","unstructured":"Hedengran A, Steensberg AT, Virgili G et al (2020) Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. Br J Ophthalmol 104(11):1512\u20131518","journal-title":"Br J Ophthalmol"},{"key":"3704_CR9","doi-asserted-by":"publisher","unstructured":"(2007) The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf 5(2):75\u201392. https:\/\/doi.org\/10.1016\/s1542-0124(12)70081-2","DOI":"10.1016\/s1542-0124(12)70081-2"},{"key":"3704_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-1-4615-2417-5_83","volume":"350","author":"RL Farris","year":"1994","unstructured":"Farris RL (1994) Tear osmolarity\u2013a new gold standard? Adv Exp Med Biol 350:495\u2013503","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"3704_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R et al (2017) TFOS DEWS II Diagnostic Methodology report. Ocul Surf 15(3):539\u2013574","journal-title":"Ocul Surf"},{"issue":"3","key":"3704_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/00003226-200404000-00010","volume":"23","author":"KK Nichols","year":"2004","unstructured":"Nichols KK, Mitchell GL, Zadnik K (2004) The repeatability of clinical measurements of dry eye. Cornea 23(3):272\u2013285","journal-title":"Cornea"},{"issue":"4","key":"3704_CR13","first-page":"221","volume":"21","author":"MA Lemp","year":"1995","unstructured":"Lemp MA (1995) Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes. CLAO J 21(4):221\u2013232","journal-title":"CLAO J"},{"issue":"6","key":"3704_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"3704_CR15","unstructured":"TearLab Inc (2016) DEWS Calculator"},{"key":"3704_CR16","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2147\/OPTH.S176605","volume":"12","author":"MA Economou","year":"2018","unstructured":"Economou MA, Laukeland HK, Grabska-Liberek I et al (2018) Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clin Ophthalmol 12:2399\u20132407","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3704_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","volume":"97","author":"JF Rouland","year":"2013","unstructured":"Rouland JF, Traverso CE, Stalmans I et al (2013) Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol 97(2):196\u2013200","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"3704_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1120672117753703","volume":"28","author":"A Hommer","year":"2018","unstructured":"Hommer A, Schmidl D, Kromus M et al (2018) Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness. Eur J Ophthalmol 28(4):385\u2013392","journal-title":"Eur J Ophthalmol"},{"key":"3704_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OPTH.S28104","volume":"6","author":"I Janulevi\u010dien\u0117","year":"2012","unstructured":"Janulevi\u010dien\u0117 I, Derka\u010d I, Grybauskiene L et al (2012) Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol\u00a0(Auckland, NZ) 6:103\u2013109","journal-title":"Clin Ophthalmol\u00a0(Auckland, NZ)"},{"key":"3704_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1755-3768.2008.01381.x","volume":"242","author":"T Hamacher","year":"2008","unstructured":"Hamacher T, Airaksinen J, Saarela V et al (2008) Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 242:14\u201319","journal-title":"Acta Ophthalmol Suppl (Oxf)"},{"key":"3704_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2147\/OPTH.S33414","volume":"6","author":"T Mizoguchi","year":"2012","unstructured":"Mizoguchi T, Ozaki M, Unoki K et al (2012) A randomized crossover study comparing tafluprost 0.0015% with travoprost 0.004% in patients with normal-tension glaucoma [corrected]. Clin Ophthalmol 6:1579\u20131584","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"3704_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1755-3768.2010.01862.x","volume":"88","author":"H Uusitalo","year":"2010","unstructured":"Uusitalo H, Pillunat LE, Ropo A (2010) Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 88(1):12\u20139","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"3704_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1185\/03007995.2010.492030","volume":"26","author":"A Hommer","year":"2010","unstructured":"Hommer A, Mohammed Ramez O, Burchert M et al (2010) IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin 26(8):1905\u201313","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"3704_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","volume":"88","author":"H Uusitalo","year":"2010","unstructured":"Uusitalo H, Chen E, Pfeiffer N et al (2010) Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 88(3):329\u2013336","journal-title":"Acta Ophthalmol"},{"key":"3704_CR25","first-page":"821","volume":"10","author":"T Walimbe","year":"2016","unstructured":"Walimbe T, Chelerkar V, Bhagat P et al (2016) Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma. Clin Ophthalmol 10:821\u2013827","journal-title":"Clin Ophthalmol"},{"key":"3704_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2147\/OPTH.S14113","volume":"4","author":"G Katz","year":"2010","unstructured":"Katz G, Springs CL, Craven ER et al (2010) Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol (Auckland, NZ) 4:1253\u20131261","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"9","key":"3704_CR27","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1097\/ICO.0b013e31823f8cb6","volume":"31","author":"A Labbe","year":"2012","unstructured":"Labbe A, Terry O, Brasnu E et al (2012) Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea 31(9):994\u2013999","journal-title":"Cornea"},{"issue":"1","key":"3704_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40123-018-0128-8","volume":"7","author":"F G\u00f3mez-Aguayo","year":"2018","unstructured":"G\u00f3mez-Aguayo F, Paczka JA, Le\u00f1ero-C\u00f3rdova R et al (2018) A phase III randomized clinical trial of a 0.5% Timolol\u2009+\u20090.2% Brimonidine\u2009+\u20092.0% Dorzolamide fixed combination, preservative-free ophthalmic solution vs. 0.5% Timolol\u2009+\u20090.2% Brimonidine\u2009+\u20092.0% Dorzolamide fixed combination in patients with controlled primary open-angle glaucoma. Ophthalmol Therapy 7(1):145\u201356","journal-title":"Ophthalmol Therapy"},{"issue":"5","key":"3704_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ajo.2010.10.032","volume":"151","author":"MA Lemp","year":"2011","unstructured":"Lemp MA, Bron AJ, Baudouin C et al (2011) Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 151(5):792\u20138 e1","journal-title":"Am J Ophthalmol."},{"key":"3704_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2147\/OPTH.S44708","volume":"8","author":"K Inoue","year":"2014","unstructured":"Inoue K (2014) Managing adverse effects of glaucoma medications. Clin Ophthalmol (Auckland, NZ) 8:903\u2013913","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"6","key":"3704_CR31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1089\/jop.2014.0124","volume":"31","author":"I Halkiadakis","year":"2015","unstructured":"Halkiadakis I, Kontadakis GA, Tsiakou D et al (2015) Effect of glaucoma medication in tear film osmolarity of patients without symptoms of ocular discomfort. J Ocul Pharmacol Ther 31(6):330\u2013334","journal-title":"J Ocul Pharmacol Ther"},{"key":"3704_CR32","doi-asserted-by":"publisher","first-page":"1319628","DOI":"10.1155\/2018\/1319628","volume":"2018","author":"WG El Hajj Moussa","year":"2018","unstructured":"El Hajj Moussa WG, Farhat RG, Nehme JC et al (2018) Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients. J Ophthalmol 2018:1319628","journal-title":"J Ophthalmol"},{"key":"3704_CR33","first-page":"112067211878528","volume":"2018","author":"M Misiuk-Hojlo","year":"2018","unstructured":"Misiuk-Hojlo M, Pomorska M, Mulak M et al (2018) The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol 2018:1120672118785280","journal-title":"Eur J Ophthalmol"},{"key":"3704_CR34","doi-asserted-by":"publisher","first-page":"3540749","DOI":"10.1155\/2017\/3540749","volume":"2017","author":"N Tokuda","year":"2017","unstructured":"Tokuda N, Kitaoka Y, Matsuzawa A et al (2017) Changes in ocular surface characteristics after switching from benzalkonium chloride-preserved latanoprost to preservative-free tafluprost or benzalkonium chloride-preserved tafluprost. J Ophthalmol 2017:3540749","journal-title":"J Ophthalmol"},{"issue":"1","key":"3704_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/IJG.0b013e3181fc8129","volume":"21","author":"M Aihara","year":"2012","unstructured":"Aihara M, Otani S, Kozaki J et al (2012) Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma 21(1):60\u201364","journal-title":"J Glaucoma"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03704-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-024-03704-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03704-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:21:08Z","timestamp":1727954468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-024-03704-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3704"],"URL":"https:\/\/doi.org\/10.1007\/s11845-024-03704-7","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"2 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}